Skip to main content

Overview

Dr. Wolf's research focuses on disordered mineral homeostasis across the spectrum of kidney disease. His team investigates the role of fibroblast growth factor 23 (FGF23) in normal phosphate and calcium homeostasis, its alterations in patients with chronic kidney disease, the adverse effects of excess FGF23 on cardiovascular health and the molecular mechanisms that underlie these risk relationships. He has consistently served as a principal investigator on National Institutes of Health (NIH) grants in basic and clinical research, epidemiology, and clinical trials.

Highlights

  1. 1
    JAMA · 2020
    PMID: 32016310PMCID: PMC7042864DOIFirst author270 citations
  2. 2
    The Journal of clinical endocrinology and metabolism · 2022
    PMID: 34850000PMCID: PMC8947794DOISenior author47 citations
  3. 3
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021
    PMID: 32049331PMCID: PMC7771981DOISenior author84 citations

Publications

325 publications

Active

3 grants
  • PI
    NYFIRST grant program
    New York State Empire State Development Fund · 2026–2030
    NYSESDF 265019-01
  • KP
    Targeting CYP24A1 in the parathyroid glands as a novel treatment of secondary hyperparathyroidism in chronic kidney disease
    American Society of Nephrology Inc · 2026–2028
    ASN 255580-01
  • PI
    Tissue-Specific Regulation and Effects of CYP24A1
    National Institute of Diabetes and Digestive and Kidney Diseases · 2024–2027
Completed grants (10)
  • Sub-PI
    HiLo - Pragmatic trial of higher vs. lower serum phosphate targets in patients undergoing hemodialysis
    National Institute of Diabetes and Digestive and Kidney Diseases · 2024–2024 · via Duke University
  • PI
    HiLo
    NIDDK · 2018–2019 · via NIH RePORTER
  • PI
    FGF23 and Cardiovascular Disease in CKD
    NIDDK · 2008–2019 · via NIH RePORTER
  • PI
    Role of FGF23 in Mineral Metabolism Across the Spectrum of Chronic Kidney Disease
    NIDDK · 2007–2019 · via NIH RePORTER
  • PI
    FGF-23 and clinical outcomes in ADPKD patients
    NIDDK · 2012–2018 · via NIH RePORTER
  • PI
    Pilot Studies Targeting Mineral Metabolism in Chronic Kidney Disease
    NIDDK · 2013–2018 · via NIH RePORTER
  • PI
    Mentored Patient Oriented Research in Mineral Metabolism
    NIDDK · 2012–2017 · via NIH RePORTER
  • PI
    FGF23 and mineral metabolism in Acute Kidney Injury
    NIDDK · 2014–2016 · via NIH RePORTER
  • PI
    Cardiovascular Disease Following Hypertensive Pregnancy
    NCRR · 2003–2008 · via NIH RePORTER
  • PI
    REDUCED PHOSPHATE INTAKE IN "NORMO-PHOSPHATEMIC" CHRONIC KIDNEY DISEASE PATIENTS
    NCRR · 2005–2008 · via NIH RePORTER

Honors & distinctions

2 honors
  • Member · Association of American Physicians
  • Member · American Society for Clinical Investigation

News mentions

External relationships

Leadership Roles

Akebia Therapeutics

Ownership

Akebia Therapeutics · Unicycive Therapeutics INC

Advisory/Scientific Board Member

Unicycive Therapeutics INC

Speaker/Lecturer

Pfizer, Inc.

Other

BridgeBio Pharma, Inc. · EvlaBio AG · Guidepoint Global LLC · Pharmacosmos Therapeutics Inc. · Vera Therapeutics INC